CLIMB BIO, INC. Marketable Securities, Unrealized Gain (Loss)
CLIMB BIO, INC. (CLYM) reported Marketable Securities, Unrealized Gain (Loss) of -$224.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$224.00K, a 800.00% decline year-over-year.
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$278.00K, a 205.70% decline year-over-year.
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$34.00K.
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $151.00K, a 24.88% decline year-over-year.
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for fiscal 2025 was $412.00K, a 1548.00% increase from fiscal 2024.
- CLIMB BIO, INC. marketable securities, unrealized gain (loss) for fiscal 2024 was $25.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$224.00K 10-Q · filed 2026-08-06 | -$502.00K 10-Q · filed 2026-08-06 | -$536.00K derived: sum of 3 quarters · filed 2026-08-06 | -$385.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$278.00K 10-Q · filed 2026-08-06 | -$312.00K derived: sum of 2 quarters · filed 2026-08-06 | -$161.00K derived: sum of 3 quarters · filed 2026-08-06 | -$129.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $117.00K derived: sum of 2 quarters · filed 2026-03-05 | $149.00K derived: sum of 3 quarters · filed 2026-08-06 | $412.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $151.00K 10-Q · filed 2025-11-06 | $183.00K derived: sum of 2 quarters · filed 2026-08-06 | $446.00K 10-Q · filed 2025-11-06 | $268.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $32.00K 10-Q · filed 2026-08-06 | $295.00K 10-Q · filed 2026-08-06 | $117.00K derived: sum of 3 quarters · filed 2026-08-06 | $318.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $263.00K 10-Q · filed 2026-08-06 | $85.00K derived: sum of 2 quarters · filed 2026-08-06 | $286.00K derived: sum of 3 quarters · filed 2026-08-06 | $286.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $23.00K derived: sum of 2 quarters · filed 2026-03-05 | $23.00K derived: sum of 3 quarters · filed 2026-03-05 | $25.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $201.00K 10-Q · filed 2025-11-06 | $201.00K derived: sum of 2 quarters · filed 2025-11-06 | $203.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $2.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $2.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |